Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 6/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 6/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 6/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 6/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.43 |
| ▸ | GSR | P00390 | 2/20 | 0.43 |
| ▸ | GRM8 | O00222 | 1/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2877061 | 1.00 | METAP1 (0.55) | METAP1SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL1224024 | 1.00 | METAP1 (0.55) | METAP1SLC1A3SLC1A2SLC1A1GRIK1 | |
| Hydrochloric Acid SCHEMBL2029962 | 0.98 | METAP1 (0.53) | METAP1SLC1A3SLC1A2SLC1A1GRIK1 | |
| Hydrochloric Acid SCHEMBL2029965 | 0.98 | METAP1 (0.53) | METAP1SLC1A3SLC1A2SLC1A1GRIK1 | |
| Hydrochloric Acid SCHEMBL2033821 | 0.98 | METAP1 (0.53) | METAP1SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL4714160 | 0.98 | METAP1 (0.52) | METAP1SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL18774953 | 0.98 | METAP1 (0.52) | METAP1SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL25356227 | 0.94 | METAP1 (0.47) | METAP1SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL25662123 | 0.94 | METAP1 (0.47) | METAP1SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL4407623 | 0.94 | METAP1 (0.47) | METAP1SLC1A3SLC1A2SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106674030-A | Preparation method of N-fluorenylmethyloxycarbonyl-L-2-amino-4-cyclohexylbutyric acid | 泰州天鸿生化科技有限公司 | 2017-05-17 | — | — | CN | claimed |
| CN-101400699-A | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions | BRISTOL MYERS SQUIBB CO (US) | 2009-04-01 | — | — | CN | claimed |
| EP-1976873-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Brystol-Myers Squibb Company (US) | 2008-10-08 | — | — | EP | claimed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | claimed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | claimed |
| EP-4540267-B1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| CN-120202010-A | Ligand-oligonucleotide conjugates and linkers for use therewith | 上海京新生物医药有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250152658-A1 | CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2025-05-15 | — | — | US | disclosed |
| US-20240317803-A1 | BCL9 PEPTIDES AND VARIANTS THEREOF | WNTRX PHARMACEUTICALS INC. | 2024-09-26 | — | — | US | disclosed |
| WO-2024083220-A1 | LIGAND-OLIGONUCLEOTIDE CONJUGATE AND LINKER FOR CONJUGATE | 上海京新生物医药有限公司 | 2024-04-25 | — | — | WO | disclosed |
| US-11866518-B2 | Bicyclic peptide ligands specific for TSLP | BICYCLETX LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| US-20230406885-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | US | disclosed |
| US-6544978-B2 | Treating Alzheimer's disease both prophylactically and therapeutically | ATHENA NEUROSCIENCES, INC. | 2003-04-08 | — | — | US | disclosed |
| US-6541466-B2 | Such as 1-(N'-(3,5-difluorophenylacetyl)-L-alaninyl)-aminodibenzosuberane; for treatment of Alzheimer's disease | ATHENA NEUROSCIENCES, INC. | 2003-04-01 | — | — | US | disclosed |
| US-5223485-A | Oligopeptides as antiinflammatory agents | ABBOTT LABORATORIES (US) | 1993-06-29 | — | — | US | disclosed |
| EP-0456758-A1 | ANAPHYLATOXIN-RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 1991-11-21 | — | — | EP | disclosed |
| WO-1990009162-A2 | ANAPHYLATOXIN-RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 1990-08-23 | — | — | WO | disclosed |
| US-4914129-A | Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups | CIBA-GEIGY CORPORATION (US) | 1990-04-03 | — | — | US | disclosed |
| US-4889869-A | ANTIALDOSTERONISM AGENTS | CIBA-GEIGY CORPORATION (US) | 1989-12-26 | — | — | US | disclosed |
| US-4758584-A | Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups | CIBA-GEIGY CORPORATION (US) | 1988-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | METAP1 355/4885SLC1A3 2595/4885SLC1A2 3742/4885 |
| US-20230406885-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | IL1A, IL1B, IL1R1 | METAP1 799/4885SLC1A3 3150/4885SLC1A2 4244/4885 |
| US-20240317803-A1 | BCL9 PEPTIDES AND VARIANTS THEREOF | BCL9, BCL9L, BCL3 | METAP1 959/4885SLC1A3 4087/4885SLC1A2 4295/4885 |
| US-11866518-B2 | Bicyclic peptide ligands specific for TSLP | TSLP, VIP, CCL2 | METAP1 334/4885SLC1A3 3997/4885SLC1A2 4555/4885 |
| US-20250152658-A1 | CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | IL1R1, IL1A, IL1B | METAP1 620/4885SLC1A3 3688/4885SLC1A2 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.